Twist Bioscience Stock Forecast, Price & News

-6.82 (-4.80 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $135.24
50-Day Range
MA: $128.93
52-Week Range
Now: $135.24
Volume411,153 shs
Average Volume1.00 million shs
Market Capitalization$6.58 billion
P/E RatioN/A
Dividend YieldN/A
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has a collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Twist Bioscience logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TWST
Year FoundedN/A



Sales & Book Value

Annual Sales$90.10 million
Book Value$7.53 per share


Net Income$-139,930,000.00
Net Margins-155.31%


Market Cap$6.58 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable


Twist Bioscience (NASDAQ:TWST) Shares Up 10.3%
April 13, 2021 |
Twist Bioscience (NASDAQ:TWST) Shares Gap Up to $128.65
April 7, 2021 |
Twist Bioscience (NASDAQ:TWST) Trading Up 7.2%
March 31, 2021 |
See More Headlines


Overall MarketRank

1.20 out of 5 stars

Medical Sector

926th out of 2,024 stocks

Biological Products, Except Diagnostic Industry

123rd out of 177 stocks

Analyst Opinion: 1.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-6.82 (-4.80 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

Is Twist Bioscience a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Twist Bioscience?

Wall Street analysts have given Twist Bioscience a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Twist Bioscience?

Twist Bioscience saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,580,000 shares, an increase of 39.8% from the February 28th total of 2,560,000 shares. Based on an average daily trading volume, of 985,200 shares, the days-to-cover ratio is currently 3.6 days.
View Twist Bioscience's Short Interest

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Twist Bioscience

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) issued its quarterly earnings results on Wednesday, February, 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. The firm had revenue of $28.16 million for the quarter, compared to analyst estimates of $25.26 million. Twist Bioscience had a negative trailing twelve-month return on equity of 44.62% and a negative net margin of 155.31%.
View Twist Bioscience's earnings history

How has Twist Bioscience's stock price been impacted by COVID-19 (Coronavirus)?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TWST stock has increased by 379.6% and is now trading at $135.24.
View which stocks have been most impacted by COVID-19

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110-118 million, compared to the consensus revenue estimate of $116.02 million.

What price target have analysts set for TWST?

5 brokerages have issued 12-month price targets for Twist Bioscience's shares. Their forecasts range from $100.00 to $200.00. On average, they expect Twist Bioscience's share price to reach $137.50 in the next year. This suggests a possible upside of 1.7% from the stock's current price.
View analysts' price targets for Twist Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Chairman, Pres & CEO (Age 48, Pay $976.51k)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 65, Pay $715.56k)
  • Mr. Patrick Weiss, Chief Operating Officer (Age 50, Pay $780.01k)
  • Dr. William Charles Banyai, Sr. VP of Advanced Devel., GM of Data Storage & Director (Age 66, Pay $591.56k)
  • Dr. Patrick John Finn, Chief Commercial Officer (Age 49, Pay $693.68k)
  • Mr. Siyuan Chen, Chief Technology Officer
  • Dr. Aaron K. Sato, Chief Scientific Officer & Chief Scientific Officer of BioPharma
  • Ms. Paula Green, Sr. VP of HR (Age 53)
  • Mr. Martin Kunz, Sr. VP of Bus. Technologies (Age 50)
  • Ms. Erin Smith, Sr. VP of Gov. Affairs & Public Policy

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience CEO Emily Leproust on Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wolff Wiese Magana LLC (0.01%), Phoenix Wealth Advisors (0.01%), Pacer Advisors Inc. (0.00%) and AdvisorNet Financial Inc (0.00%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends for Twist Bioscience

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, and William Banyai.
View insider buying and selling activity for Twist Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was acquired by a variety of institutional investors in the last quarter, including Wolff Wiese Magana LLC, AdvisorNet Financial Inc, and Phoenix Wealth Advisors.
View insider buying and selling activity for Twist Bioscience
or or view top insider-buying stocks.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $135.24.

How much money does Twist Bioscience make?

Twist Bioscience has a market capitalization of $6.58 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

How many employees does Twist Bioscience have?

Twist Bioscience employs 525 workers across the globe.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is

Where are Twist Bioscience's headquarters?

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]

This page was last updated on 4/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.